SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cytokinetics, Incorporated ( CYTK)
CYTK 64.12+1.3%Dec 24 12:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: mopgcw10/11/2013 7:02:49 PM
   of 405
 
fwiw: Needham reiterated a Buy rating and raised his price target from $20 to $25.

"Omecamtiv is poised to enter a pivotal study in 2014, triggering a milestone payment for CYTK shareholders and giving them a "free option" on significant economics in a blockbuster indication. Despite this progress, CYTK shares are trading well off their 52-week high following a Phase IIb omecamtiv readout that met all of our expectations but was touted by the media as a headline failure. Cytokinetics also has a wholly owned drug to treat skeletal muscle disorders with a key Phase IIb readout in early 2014 and a partnered 2nd-generation skeletal muscle program with Astellas."

"While the primary analysis of 3 pooled doses vs. placebo on the endpoint of dyspnea (shortness of breath) was not significant, the highest dose of omecamtiv did show significant improvement. Importantly, omecamtiv showed significant increases in systolic injection and reduction in worsening of heart failure while actually lowering heart rate, which distinguishes omecamtiv from the older inotropic agents. We believe these results are more than positive enough for Amgen to proceed with a planned Phase III study next year, triggering a milestone payment to CYTK shareholders and giving a "free option" on significant economics in a blockbuster indication."

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext